<DOC>
	<DOCNO>NCT01883505</DOCNO>
	<brief_summary>This phase 2a randomize double blind placebo control , 30 Parkinson 's disease ( PD ) subject treated oral levodopa/carbidopa ( LD/CD ) suffer motor fluctuation . The aim study determine safety , tolerability , levodopa pharmacokinetics , need oral LD dose adjustment usability ambulatory drug delivery pump follow repeat dose ND0612 conventional home set Parkinson 's disease patient . Safety tolerability , pharmacokinetic profile levodopa carbidopa , pump usability potential clinical effect ND0612 explore subject PD motor fluctuation .</brief_summary>
	<brief_title>A Phase 2a Study Followed Evaluate Safety , Tolerability Levodopa Pharmacokinetics Levodopa-treated Parkinson 's Disease Patients Receiving ND0612</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Men woman idiopathic Parkinson 's disease 2 . Subjects must experience motor fluctuation associate LD/CD dose 3 . Modified Hoehn Yahr stage &lt; 5 4 . Subjects must take optimized stable levodopa/dopa decarboxylase inhibitor therapy 5 . Subjects treat dopaminergic agonist antiPD drug stable dos 6 . Women must postmenopausal , surgically sterilize , use adequate birth control . Women childbearing potential must negative pregnancy test ( serum betaHCG ) screening . 7 . Subjects must age 30 old . 8 . Subjects must willing able give inform consent 1 . Subjects treat entacapone , tolcapone , stalevo control release formulation levodopa/carbidopa . 2 . Subjects clinically significant unstable medical surgical condition 3 . History melanoma significant skin disorder 4 . Subjects significant cognitive impairment 5 . Subjects treat unstable dos dopaminergic agonist , anticholinergic , Monoamine oxidase ( MAO ) B inhibitor , antipsychotic 6 . Subjects clinically significant psychiatric illness 7 . Subjects history alcohol substance abuse 8 . Subjects take experimental medication within 60 day prior baseline . 9 . Subject undergone neurosurgical intervention Parkinson 's disease ( e.g. , pallidotomy , thalamotomy , transplantation deep brain stimulation ) . 10 . Subjects severe disable dyskinesia . 11 . Subjects hear , visual motor impairment prevent use pump react effectively error</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Motor fluctuation</keyword>
	<keyword>levodopa pharmacokinetics</keyword>
	<keyword>levodopa carbidopa solution</keyword>
	<keyword>continuous subcutaneous delivery</keyword>
	<keyword>Patch-pump</keyword>
</DOC>